Stockscreener 앱 받기
0.9503
4.06%
-0.0402
시간 외 거래:
.93
-0.0203
-2.14%
Neurosense Therapeutics Ltd 주식(NRSN)의 최신 뉴스
Weekly Trades: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changes2025 Volatility Report & Growth Focused Stock Reports - baoquankhu1.vn
Ideas Watch: Will NeuroSense Therapeutics Ltd face regulatory challengesWeekly Trend Report & Technical Pattern Based Signals - baoquankhu1.vn
Weekly Trades: Why is NeuroSense Therapeutics Ltd stock going downInsider Selling & Daily Profit Focused Screening - baoquankhu1.vn
Aug Highlights: Is SNOA likely to announce a buybackIPO Watch & Fast Entry High Yield Tips - baoquankhu1.vn
Earnings Recap: Will NeuroSense Therapeutics Ltd Equity Warrant stock go up in YEARJuly 2025 Outlook & Technical Entry and Exit Tips - baoquankhu1.vn
RSI Check: Why NeuroSense Therapeutics Ltd stock appeals to analysts2025 Breakouts & Breakdowns & Daily Profit Focused Stock Screening - Bộ Nội Vụ
Bear Alert: Can NeuroSense Therapeutics Ltd stock beat analyst upgradesJuly 2025 Price Swings & Weekly High Momentum Picks - Bộ Nội Vụ
Risk Hedge: Is NeuroSense Therapeutics Ltd stock a good choice for value investorsJuly 2025 PostEarnings & Verified Swing Trading Watchlists - Bộ Nội Vụ
How NeuroSense Therapeutics Ltd. stock benefits from tech adoptionEarnings Recap Summary & Verified Entry Point Signals - Улправда
Why NeuroSense Therapeutics Ltd. Equity Warrant stock appeals to analystsProfit Target & Weekly High Return Stock Forecasts - Улправда
Will NeuroSense Therapeutics Ltd. stock remain a Wall Street favorite2025 Volume Leaders & Stepwise Entry and Exit Trade Signals - Улправда
Technical Analysis: What risks investors should watch in NeuroSense Therapeutics Ltd stockRate Cut & Verified Stock Trade Ideas - Bộ Nội Vụ
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB - Sahm
What risks investors should watch in NeuroSense Therapeutics Ltd. stockForecast Cut & Precise Swing Trade Entry Alerts - ulpravda.ru
Is NeuroSense Therapeutics Ltd. stock resilient to inflationGlobal Markets & Weekly High Momentum Picks - Улправда
Will NeuroSense Therapeutics Ltd. Equity Warrant stock recover faster than peersJuly 2025 WrapUp & Weekly Market Pulse Updates - Улправда
NeuroSense Therapeutics Ltd.Ordinary Shares (NQ: NRSN - FinancialContent
How NeuroSense Therapeutics Ltd. Equity Warrant stock responds to policy changesWeekly Risk Summary & Weekly High Potential Alerts - Улправда
Can NeuroSense Therapeutics Ltd. stock resist sector downturnsWeekly Investment Recap & High Return Stock Watch Alerts - Улправда
Trading Recap: Will NeuroSense Therapeutics Ltd. (H1Z) stock justify high valuation2025 Price Momentum & Fast Gain Stock Tips - Улправда
Can NeuroSense Therapeutics Ltd. stock continue upward trendBreakout Watch & Free AI Powered Buy and Sell Recommendations - Улправда
Is NeuroSense Therapeutics Ltd. Equity Warrant stock a good choice for value investors2025 Support & Resistance & Precise Swing Trade Alerts - Улправда
NeuroSense Therapeutics Ltd. Appoints Prof. Steven E. Arnold to Scientific Advisory Board - MarketScreener
Hedge Fund Bets: How NeuroSense Therapeutics Ltd. Equity Warrant stock performs after earningsJuly 2025 Intraday Action & Weekly Setup with ROI Potential - Улправда
Harvard Alzheimer’s doctor joins biotech developing neurodegenerative treatments - Stock Titan
NeuroSense Shareholders Approve Equity Grants to Directors and CEO to Preserve Cash - TipRanks
How NeuroSense Therapeutics Ltd. stock compares to growth peers2026 world cup usa national team semifinals defensive leaders set piece tactics match prediction analysis - ulpravda.ru
NeuroSense Therapeutics (NASDAQ:NRSN) Upgraded by Wall Street Zen to Hold Rating - Defense World
NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) Short Interest Down 15.5% in December - Defense World
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Weekly Buzz: FDA OKs Roche's Lunsumio VELO; It's No For Tolbrutinib; BioMarin, SNY Open Wallets - RTTNews
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study - Sahm
NeuroSense Unveils Favourable Safety Analysis Data Of PrimeC In NST-AD-001 Study For Alzheimer's - Nasdaq
NeuroSense Therapeutics (NASDAQ:NRSN) Receives Buy Rating from D. Boral Capital - Defense World
D. Boral Capital Maintains NeuroSense Therapeutics (NRSN) Buy Recommendation - Nasdaq
NeuroSense Reports Favorable Safety Profile for PrimeC in Phase 2 Alzheimer’s Trial - TipRanks
Neurosense stock rises as Alzheimer’s drug shows favorable safety profile By Investing.com - Investing.com South Africa
Neurosense stock rises as Alzheimer’s drug shows favorable safety profile - Investing.com
Experimental Alzheimer's combo shows no serious side effects in trial - Stock Titan
Rally Mode: Is Capella Minerals Limited (N7D) stock worth buying before Fed actionEarnings Overview Summary & Safe Capital Investment Plans - moha.gov.vn
Will NeuroSense Therapeutics Ltd. stock pay special dividends2025 Volume Leaders & Verified Swing Trading Watchlists - Улправда
ETF Watch: Can NeuroSense Therapeutics Ltd. (H1Z) stock sustain institutional flowsJuly 2025 Recap & Fast Gain Swing Trade Alerts - DonanımHaber
How NeuroSense Therapeutics Ltd. (H1Z) stock compares with tech leaders2025 Stock Rankings & Low Volatility Stock Suggestions - Улправда
It had formed inverted head and shoulders earlier soon it gave a break out of the pattern.2025 Historical Comparison & High Conviction Buy Zone Alerts - Bollywood Helpline
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requi - GuruFocus
Whale Trades: What dividend safety rating applies to NeuroSense Therapeutics Ltd H1Z stockJuly 2025 Fed Impact & Weekly High Conviction Trade Ideas - moha.gov.vn
NeuroSense Therapeutics Schedules Shareholder Meeting to Approve Equity Compensation - MSN
Wall Street Zen Downgrades NeuroSense Therapeutics (NASDAQ:NRSN) to Sell - Defense World
Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period (2025-2034) | DelveInsight - Yahoo Finance
4.73%
0.92%
자본화:
|
볼륨(24시간):